Dutch pharmaceutical firm Tiofarma loses major contract citing US tariff threats

Tiofarma has reported a 20% revenue decline following the loss of a key contract, which the company attributes to uncertainty surrounding potential US import tariffs. It remains unclear if the contract termination was a direct result of specific policy implementation or preemptive risk mitigation by the client.